IRD Opus Genetics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRD

Price (delayed)

$4.57

Market cap

$371.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

$312.02M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19
Highlights
The quick ratio has grown by 8% from the previous quarter
The company's EPS has shrunk by 66% QoQ but it rose by 37% YoY
The company's net income has shrunk by 116% QoQ and by 82% YoY
The revenue is down by 16% since the previous quarter and by 12% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rexahn.com
Peers: OPK ORGO

Key stats

What are the main financial stats of IRD

IRD stock price

How has the Opus Genetics stock price performed over time
Intraday
8.81%
1 week
8.81%
1 month
-12.45%
1 year
361.62%
YTD
127.36%
QTD
0.44%

Financial performance

How have Opus Genetics's revenue and profit performed over time
Revenue
$11.98M
Gross profit
$11.98M
Operating income
-$43.03M
Net income
-$106.93M
Gross margin
100%
Net margin
-892.4%
Opus Genetics's net margin has shrunk by 155% QoQ and by 108% YoY
The company's net income has shrunk by 116% QoQ and by 82% YoY
The operating income has grown by 33% YoY but it has contracted by 11% from the previous quarter
The operating margin has declined by 32% since the previous quarter but it has increased by 24% year-on-year

Price vs fundamentals

How does IRD's price correlate with its fundamentals

Growth

What is Opus Genetics's growth rate over time

Valuation

What is Opus Genetics stock price valuation
P/E
N/A
P/B
N/A
P/S
33.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.04
The company's EPS has shrunk by 66% QoQ but it rose by 37% YoY
IRD's P/S is 127% above its last 4 quarters average of 13.4 but 53% below its 5-year quarterly average of 64.2
The revenue is down by 16% since the previous quarter and by 12% year-on-year

Efficiency

How efficient is Opus Genetics business performance
The company's return on sales has shrunk by 156% QoQ and by 107% YoY
IRD's ROA has plunged by 95% from the previous quarter and by 62% YoY

Dividends

What is IRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRD.

Financial health

How did Opus Genetics financials performed over time
Opus Genetics's total assets is 24% lower than its total liabilities
The total liabilities has surged by 152% since the previous quarter
Opus Genetics's total assets has increased by 39% YoY and by 33% QoQ
Opus Genetics's debt is 100% higher than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.